IP Verse

Novartis International Pharmaceutical Ag opposition analysis

COMPANY ANALYSIS

Latest patents of Novartis International Pharmaceutical Ag opposed by its competitors

Patent:
EP3345602
Grant Date:
Apr 6, 2022
Title:
Rapamycin Derivative For Treating Advanced Solid Tumours
Oppositions:
3
Patent:
EP3351246
Grant Date:
Sep 18, 2019
Title:
Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated Angiogenesis
Oppositions:
9
Patent:
EP3342411
Grant Date:
Aug 21, 2019
Title:
Rapamycin Derivative For Treating Pancreas Cancer
Oppositions:
10
Patent:
EP3143995
Grant Date:
Dec 5, 2018
Title:
A Rapamycin Derivative For Treating Lung Cancer
Oppositions:
7

Competitors of Novartis International Pharmaceutical Ag

ETHYPHARM

STADA ARZNEIMITTEL AG

ACCORD HEALTHCARE LTD

Want to track Novartis International Pharmaceutical Ag?

Feel free to send us a message here and we will get back to you